U.S. markets closed
  • S&P 500

    4,247.44
    +8.26 (+0.19%)
     
  • Dow 30

    34,479.60
    +13.36 (+0.04%)
     
  • Nasdaq

    14,069.42
    +49.09 (+0.35%)
     
  • Russell 2000

    2,335.81
    +24.40 (+1.06%)
     
  • Crude Oil

    70.78
    +0.49 (+0.70%)
     
  • Gold

    1,879.50
    -16.90 (-0.89%)
     
  • Silver

    28.05
    +0.02 (+0.07%)
     
  • EUR/USD

    1.2107
    -0.0071 (-0.58%)
     
  • 10-Yr Bond

    1.4620
    +0.0030 (+0.21%)
     
  • GBP/USD

    1.4117
    -0.0060 (-0.42%)
     
  • USD/JPY

    109.6350
    +0.2870 (+0.26%)
     
  • BTC-USD

    35,950.37
    -1,514.46 (-4.04%)
     
  • CMC Crypto 200

    924.19
    -17.62 (-1.87%)
     
  • FTSE 100

    7,134.06
    +45.88 (+0.65%)
     
  • Nikkei 225

    28,948.73
    -9.83 (-0.03%)
     

UPDATE 1-German panel to recommend J&J COVID vaccine for over-60s - Spiegel

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

(Adds RKI comment, background)

BERLIN, May 7 (Reuters) - Germany's vaccine committee, known as STIKO, plans to recommend Johnson & Johnson's COVID-19 vaccine only for people over the age of 60, German magazine Der Spiegel reported on Friday, citing no sources.

Europe's drug regulator approved J&J's vaccine last month after examining cases of a rare blood clotting issue in U.S. adults who received a dose. But it left it up to the European Union's member states to decide how to use it.

A spokeswoman for the Robert Koch Institute (RKI) for infectious diseases said the institute expects STIKO to make a recommendation on J&J's vaccine next week. She declined to comment further.

Germany limited the shot from Anglo-Swedish drugmaker AstraZeneca to people over 60 after post-vaccination monitoring found rare - and sometimes fatal - cases of blood clotting, with younger women disproportionately affected.

Health Minister Jens Spahn announced on Thursday that Germany would make AstraZeneca available to all adults, regardless of age, to speed up its vaccination campaign.

The decision by the federal government follows moves by several German states to make AstraZeneca more widely available and comes as the pace of giving shots of mainstay vaccines from BioNTech/Pfizer and Moderna picks up.

(Reporting by Maria Sheahan Editing by Riham Alkousaa and Thomas Escritt)